Germany, FranceFrance

Two rulings send different signs for green biotech

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of GM crops consternated: They declared the French ban on the cultivation of GM maize by Monsanto illegal. Though the French authorities did have the right to impose a moratorium on the growing of Monsanto's insect-resistant MON810 maize, they based the decision on the wrong EU legislation, the judges said. France will, if necessary, issue a new ban on the genetically modified maize of US biochemicals company Monsanto, Environment Minister Nathalie Kosciusko-Morizet said, after the European Court of Justice ruled France's current ban on the maize was defective. 'If the French clause is cancelled for procedural reasons, we will take out a new safeguard clause (...) because the environmental questions (around MON 810) are still unanswered,' Kosciusko-Morizet said. The matter now lies with the Council of State, France's highest court on matters of public administration. Petitioned by Monsanto, the Council asked the European Court of Justice for an opinion on whether the country could justify its unilateral ban under the EU directive.
In another decision two days earlier, the Court sent the GM proponents in Germany and Europe reeling. It ruled that honey which contains trace amounts of pollen from genetically modified (GM) corn must be undergo full safety authorisation before it can be sold as food. In what green groups are calling a "groundbreaking" ruling, the decision could force the EU to strengthen its already near-zero tolerance policy on genetically modified organisms (GMOs). Bavarian beekeepers claimed their honey had been "contaminated" by pollen from a nearby test field for Monsanto maize. In response to the rulings, the European Commission will in two weeks discuss the issue of GMOs with EU member states.

FranceFrance

05.01.2012

Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/two-rulings-send-different-signs-for-green-biotech.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • FORMYCON9.74 EUR9.44%
  • CYTOS0.29 CHF3.57%
  • BAYER118.00 EUR3.42%

FLOP

  • MAGFORCE6.12 EUR-2.55%
  • SARTORIUS95.00 EUR-2.06%
  • ADDEX3.01 CHF-1.95%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.25 EUR48.7%
  • STRATEC BIOMEDICAL48.65 EUR25.2%

FLOP

  • BIOFRONTERA2.53 EUR-12.8%
  • ADDEX3.01 CHF-8.8%
  • CO.DON2.53 EUR-8.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.53 EUR141.0%
  • BB BIOTECH182.60 EUR64.6%

FLOP

  • CYTOS0.29 CHF-91.5%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.39 EUR-41.1%

No liability assumed, Date: 23.11.2014

Current issue

All issues